EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Challenges of Conducting Risk‐Benefit Analysis of Early Phase Clinical Trials: Results of a National Survey of IRB Chairs

Christine M Baugh, Dragana Bolcic-Jankovic, Mark Fedyk, Mark Yarborough, Spencer Phillips Hey, Insoo Hyun, Jonathan Kimmelman, Eric G Campbell

Ethics & Human Research · 2025

DOI: 10.1002/eahr.60024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ethics & Human Research, 2025. Verfasst von Christine M Baugh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Assistant professor at the University of Colorado Anschutz School of Medicine in the Department of Medicine in the Division of General Internal Medic…. Hauptthemen laut MEDLINE: Ethics Committees, Research, Clinical Trials as Topic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Institutes of Neurologic Diseases and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Institutional review boards (IRBs) are charged with conducting risk‐benefit analysis for early phase clinical trials that often involve high levels of uncertainty regarding a trial's potential risks and benefits. Our study used a survey of IRB chairs to explore how IRBs conduct risk‐benefit analysis, the unique facets of risk‐benefit analysis for early phase clinical trials and specifically for early phase neurology trials, and what facilitates high‐quality risk‐benefit analysis. The survey measured IRB chairs’ perceived difficulty, preparedness, processes, and satisfaction with risk‐benefit analysis for early phase trials. The survey was completed by 148 of the 259 eligible IRB chairs for a response rate of 64.6%. Two‐thirds of respondents found risk‐benefit analysis for early phase clinical trials more challenging than for later phase trials. Ninety‐one percent of respondents felt that their IRB did an “excellent” or “very good” job conducting risk‐benefit analysis, but more than one‐third of respondents did not feel “very prepared” to conduct key aspects of risk‐benefit analysis. Over two‐thirds of respondents reported that additional resources, like a standardized process for conducting risk‐benefit analysis, would be mostly or very valuable. Our results suggest that conducting risk‐benefit analysis for early phase clinical trials generally and early phase neurology trials specifically is challenging for IRBs. One‐third of respondents reported that they lack preparation for assessing the scientific value of these types of trials and the risks and benefits to research participants, and a majority desire additional support.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ethics Committees, ResearchClinical Trials as TopicHumansSurveys and QuestionnairesRisk Assessment

Stichwörter der Autor:innen

clinical trialsearly phase clinical trialshuman research ethicsinstitutional review boards (IRBs)risk‐benefit analysis

Autor:innen und Institutionen

  • Assistant professor at the University of Colorado Anschutz School of Medicine in the Department of Medicine in the Division of General Internal Medicine and Center for Bioethics and Humanities at the University of Color…
  • Senior research fellow at the Center for Survey Research at the University of Massachusetts Boston.
  • Professor in the Division of General Medicine and Bioethics in the Department of Internal Medicine at the School of Medicine & Betty Irene Moore School of Nursing at the University of California, Davis.
  • Professor emeritus in the division of general medicine and bioethics in the Department of Internal Medicine at the School of Medicine at the University of California, Davis.
  • Chief science officer at Prism Analytic Technologies.
  • Director of the Center for Life Sciences and Public Learning in the Museum of Science, Boston and an affiliate of Harvard Medical School's Center for Bioethics.

Förderung

  • NINDS NIH HHS
  • National Institutes of Neurologic Diseases and Stroke

Zitieren

APA

Baugh, C. M., Bolcic-Jankovic, D., Fedyk, M., Yarborough, M., Hey, S. P., Hyun, I., Kimmelman, J., & Campbell, E. G. (2025). Challenges of Conducting Risk‐Benefit Analysis of Early Phase Clinical Trials: Results of a National Survey of IRB Chairs. Ethics & Human Research. https://doi.org/10.1002/eahr.60024

Vancouver

Baugh CM, Bolcic-Jankovic D, Fedyk M, Yarborough M, Hey SP, Hyun I, et al. Challenges of Conducting Risk‐Benefit Analysis of Early Phase Clinical Trials: Results of a National Survey of IRB Chairs. Ethics & Human Research. 2025. doi:10.1002/eahr.60024

BibTeX
@article{Baugh2025,
  author = {Baugh, Christine M and Bolcic-Jankovic, Dragana and Fedyk, Mark and Yarborough, Mark and Hey, Spencer Phillips and Hyun, Insoo and Kimmelman, Jonathan and Campbell, Eric G},
  title = {Challenges of Conducting Risk‐Benefit Analysis of Early Phase Clinical Trials: Results of a National Survey of IRB Chairs},
  journal = {Ethics & Human Research},
  year = {2025},
  doi = {10.1002/eahr.60024}
}
Kostenlos starten →